Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease

This study has been completed.
Sponsor:
Collaborator:
Ortho-McNeil Neurologics, Inc.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00082602
First received: May 12, 2004
Last updated: May 19, 2011
Last verified: April 2009

May 12, 2004
May 19, 2011
May 2004
Not Provided
The primary end point occurs at Week 8. The primary outcome measures will be tolerability and safety through rates of adverse events.
Not Provided
Complete list of historical versions of study NCT00082602 on ClinicalTrials.gov Archive Site
The secondary end point occurs at Week 12. The secondary outcome measure will be the Mini Mental State Examination score.
Not Provided
Not Provided
Not Provided
 
Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease
Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease

The purpose of this study is to evaluate the safety and tolerability of an extended release formulation of the drug galantamine using a rapid dose escalation regimen.

To improve dosing convenience of the current formulation of galantamine, a new once daily dosing Extended Release (ER) formulation was developed. In a different large study, in which approximately 900 patients with Alzheimer's disease participated, efficacy of the Extended Release formulation was confirmed. During the first 8 weeks of treatment, nausea and vomiting occurred less frequently with the Extended Release than Intermittent Release formulation. This suggests that patients might better tolerate a rapid dose escalation to the initial maintenance dose of 16mg daily, thereby improving the risk/benefit ratio during the first 4 weeks of therapy, i.e. receiving more drug sooner. The trial objectives are: 1) to demonstrate the safety and tolerability of galantamine Extended Release 16 mg daily when titrated from 8 mg daily after one week; 2) to evaluate the effect of galantamine Extended Release on cognition as measured by the Mini Mental State Examination. Results from prior trials show that galantamine Intermittent Release (twice a day dosing) has a high rate of adverse events when dose escalations occur at one-week intervals. Therefore, current galantamine labelling recommends that the drug dose be escalated once every 4 weeks. The study hypotheis is that the rapid dose escalation of the Extended Release formulation in subjects with Alzheimer's disease is safe and well tolerated. Comparison of adverse event rates will be made to the first 8 weeks Reminyl Extended Release group of another trial in which the Extended Release formulation was titrated from 8 mg daily to 16 mg daily at 4 weeks. Subjects will receive galantamine Extended Release capsules by mouth starting at 8 mg daily and after one week will be titrated up to 16 mg daily. This dose will be maintained for 11 additional weeks.

8 mg of Galantamine Extended Release Capsules once daily for one week. After one week will be titrated up to 16 mg daily for 11 weeks.

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Alzheimer's Disease
Drug: galantamine ER
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
83
April 2005
Not Provided

Inclusion Criteria:

  • Male or female outpatients diagnosed with Alzheimer's Disease
  • Age >= 60 years
  • Presence of mild to moderate dementia as evidenced by Mini Mental State Examination (MMSE) score of 10-24 inclusive at screening
  • History of cognitive decline that had been gradual in onset and progressive over a period of at least six months

Exclusion Criteria:

  • Neurodegenerative disorders
  • One of the following conditions possibly resulting in cognitive impairment: Acute cerebral trauma or injuries secondary to chronic trauma (such as boxing), hypoxic cerebral damage, whether or not due to acute or chronic cerebral hypoperfusion
  • Vitamin deficiency states, such as folate, vitamin B12 or other B complex deficiencies
  • Neurosyphilis or other infections resulting in cerebral abscesses, meningitis, or encephalitides such as AIDS
  • Primary or metastatic cerebral neoplasia
  • Significant endocrine or metabolic disease e.g., untreated or uncontrolled thyroid, parathyroid or pituitary disease, Cushing's syndrome, severe renal failure or uncontrolled diabetes mellitus
  • Mental retardation or oligophrenia
  • Multi-infarct dementia or clinically active cerebrovascular disease as evidenced by: a history of a significant cerebrovascular event yielding a physical or neurologic deficit likely to confound the assessment of the subject's intellectual function, multiple focal signs on neurological examination indicative of multiple ischemic attacks, significant findings on an available CT or MRI scan taken within the last 12 months
  • Subjects with the following co-existing medical conditions: Any history of epilepsy or convulsions except for febrile convulsions during childhood
  • Current clinically significant psychiatric disease, in particular current major depression, schizophrenia, bipolar disorder, moderate to severe or uncontrolled behavioral disturbances
  • Peptic ulcer disease: if the ulcer is considered to be still active, or if treatment is not successful (symptoms present)
  • Clinically significant hepatic, renal, pulmonary, metabolic or endocrine disturbances
  • Clinically significant urinary outflow obstruction
  • Current, clinically significant cardiovascular disease that would be expected to limit the subject's ability to participate in and complete a 12-Week trial. The following would usually be considered clinically significant cardiovascular diseases: cardiac surgery or myocardial infarction within the past 6 months, angina or coronary artery disease that required a change in anti-angina medication within the last 3 months, decompensated congestive heart failure, cardiac disease potentially resulting in syncope, near syncope or other alterations of mental status, atrial fibrillation, bradycardia < 50/min., atrio-ventricular block > first degree
  • Severe mitral or aortic valvular disease
  • Uncontrolled high blood pressure (systolic blood pressure > 170 mmHg or diastolic blood pressure > 110 mmHg) or sustained hypotension
  • Any agent being used for the treatment of dementia (approved, experimental or over the counter agents
  • Subjects who have previously received Cognexâ, Ariceptâ, metrifonate, Exelonâ, Reminyl, or Namendaâ for treatment of Alzheimer's disease, no matter if approved or experimental can be included in this trial provided that during the 30 days prior to baseline they were not taking these agents
  • O History of drug or alcohol abuse within the last year or prior prolonged history of the same
  • Female subjects of childbearing potential
  • Subjects who in the opinion of the investigator are otherwise unsuitable for a trial of this type
  • History of severe drug allergy or hypersensitivity, including recorded hypersensitivity to cholinesterase inhibitors, choline agonists or identical agents, or bromide
  • Subjects who have previously been enrolled in other galantamine trials
  • Subjects who have received an investigational medication within the last 30 days
  • Conditions that could interfere with the absorption of the compound or with the evaluation of the disease
  • Employees of the investigator
Both
60 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00082602
CR004699
Not Provided
Not Provided
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho-McNeil Neurologics, Inc.
Study Director: Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP